APO Research
Talk to an analyst

APO RESEARCH · REPORT

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchTreatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) include Tonghua Zhongsheng Pharmaceutical, Zhengzhou Taifeng Pharmaceutical, Shapuaisi Pharma, Luoxin Pharmaceutical, Zydus Pharms, Teva, Pfizer, Avet Pharmaceuticals and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size, projected growth trends, production technologies, key applications, and end-use industries.

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Company

Tonghua Zhongsheng Pharmaceutical

Zhengzhou Taifeng Pharmaceutical

Shapuaisi Pharma

Luoxin Pharmaceutical

Zydus Pharms

Teva

Pfizer

Avet Pharmaceuticals

AstraZeneca

Alnylam Pharmaceuticals

Akcea Therapeutics

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Type

RNA Interference

Antisense Oligonucleotides

Transthyretin Tetramer Stabilizer

Other

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Trends Table 2. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Drivers Table 3. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Opportunities and Challenges Table 4. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Restraints Table 5. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Manufacturers Table 9. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturers, Product Type & Application Table 13. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of RNA Interference Table 17. Major Manufacturers of Antisense Oligonucleotides Table 18. Major Manufacturers of Transthyretin Tetramer Stabilizer Table 19. Major Manufacturers of Other Table 20. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (K Units) Table 22. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2027-2032) & (K Units) Table 23. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Type (2021-2026) Table 24. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Type (2027-2032) Table 25. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Type (2021-2026) & (K Units) Table 27. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Type (2027-2032) & (K Units) Table 28. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Type (2021-2026) Table 29. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital and Clinic Table 31. Major Manufacturers of Retail Pharmacies Table 32. Major Manufacturers of Other Table 33. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (K Units) Table 35. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2027-2032) & (K Units) Table 36. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2021-2026) Table 37. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2027-2032) Table 38. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application (2021-2026) & (K Units) Table 40. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application (2027-2032) & (K Units) Table 41. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application (2021-2026) Table 42. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application (2027-2032) Table 43. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2021-2026) & (K Units) Table 45. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Region (2021-2026) Table 46. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 50. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2027-2032) & (K Units) Table 51. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 53. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2027-2032) & (K Units) Table 60. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Region (2021-2026) Table 64. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Region (2027-2032) Table 65. Tonghua Zhongsheng Pharmaceutical Company Information Table 66. Tonghua Zhongsheng Pharmaceutical Business Overview Table 67. Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 69. Tonghua Zhongsheng Pharmaceutical Recent Development Table 70. Zhengzhou Taifeng Pharmaceutical Company Information Table 71. Zhengzhou Taifeng Pharmaceutical Business Overview Table 72. Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 74. Zhengzhou Taifeng Pharmaceutical Recent Development Table 75. Shapuaisi Pharma Company Information Table 76. Shapuaisi Pharma Business Overview Table 77. Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 79. Shapuaisi Pharma Recent Development Table 80. Luoxin Pharmaceutical Company Information Table 81. Luoxin Pharmaceutical Business Overview Table 82. Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 84. Luoxin Pharmaceutical Recent Development Table 85. Zydus Pharms Company Information Table 86. Zydus Pharms Business Overview Table 87. Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 89. Zydus Pharms Recent Development Table 90. Teva Company Information Table 91. Teva Business Overview Table 92. Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 94. Teva Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 99. Pfizer Recent Development Table 100. Avet Pharmaceuticals Company Information Table 101. Avet Pharmaceuticals Business Overview Table 102. Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 104. Avet Pharmaceuticals Recent Development Table 105. AstraZeneca Company Information Table 106. AstraZeneca Business Overview Table 107. AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 109. AstraZeneca Recent Development Table 110. Alnylam Pharmaceuticals Company Information Table 111. Alnylam Pharmaceuticals Business Overview Table 112. Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 114. Alnylam Pharmaceuticals Recent Development Table 115. Akcea Therapeutics Company Information Table 116. Akcea Therapeutics Business Overview Table 117. Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 119. Akcea Therapeutics Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Distributors List Table 123. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Image Figure 2. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size (2021-2032) & (US$ Million) Figure 4. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (2021-2032) & (K Units) Figure 5. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. RNA Interference Image Figure 9. Antisense Oligonucleotides Image Figure 10. Transthyretin Tetramer Stabilizer Image Figure 11. Other Image Figure 12. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Type (2021-2032) Figure 15. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Type (2021-2032) Figure 18. Hospital and Clinic Image Figure 19. Retail Pharmacies Image Figure 20. Other Image Figure 21. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2021-2032) Figure 24. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application (2021-2032) Figure 27. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2032) Figure 29. U.S. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2032) Figure 34. Germany Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2032) Figure 41. China Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2032) Figure 49. Brazil Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (2021-2032) & (US$ Million) Figure 60. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (2021-2032) & (US$ Million) Figure 62. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • RNA Interference
  • Antisense Oligonucleotides
  • Transthyretin Tetramer Stabilizer
  • Other
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Tonghua Zhongsheng Pharmaceutical
  • Zhengzhou Taifeng Pharmaceutical
  • Shapuaisi Pharma
  • Luoxin Pharmaceutical
  • Zydus Pharms
  • Teva
  • Pfizer
  • Avet Pharmaceuticals
  • AstraZeneca
  • Alnylam Pharmaceuticals
  • Akcea Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Dynamics
  1. 2.1 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Trends
  2. 2.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Drivers
  3. 2.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Opportunities and Challenges
  4. 2.4 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Restraints
3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by Manufacturers
  1. 3.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturers, Product Type & Application
  7. 3.7 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Tier 1, Tier 2, and Tier 3
4 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by Type
  1. 4.1 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Type Introduction
  2. 4.1.1 RNA Interference
  3. 4.1.2 Antisense Oligonucleotides
  4. 4.1.3 Transthyretin Tetramer Stabilizer
  5. 4.1.4 Other
  6. 4.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type
  7. 4.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2032)
  9. 4.2.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Type (2021-2032)
  10. 4.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Type
  11. 4.3.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Type (2021-2032)
  13. 4.3.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Type (2021-2032)
5 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by Application
  1. 5.1 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application
  6. 5.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2032)
  8. 5.2.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2021-2032)
  9. 5.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application
  10. 5.3.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application (2021-2032)
  12. 5.3.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application (2021-2032)
6 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region
  1. 6.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2021-2032)
  3. 6.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2021-2026)
  4. 6.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region
  1. 7.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region
  2. 7.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region (2021-2026)
  4. 7.1.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region (2027-2032)
  5. 7.1.4 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (2021-2032)
  8. 7.2.2 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (2021-2032)
  11. 7.3.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Tonghua Zhongsheng Pharmaceutical
  2. 8.1.1 Tonghua Zhongsheng Pharmaceutical Company Information
  3. 8.1.2 Tonghua Zhongsheng Pharmaceutical Business Overview
  4. 8.1.3 Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  6. 8.1.5 Tonghua Zhongsheng Pharmaceutical Recent Developments
  7. 8.2 Zhengzhou Taifeng Pharmaceutical
  8. 8.2.1 Zhengzhou Taifeng Pharmaceutical Company Information
  9. 8.2.2 Zhengzhou Taifeng Pharmaceutical Business Overview
  10. 8.2.3 Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  12. 8.2.5 Zhengzhou Taifeng Pharmaceutical Recent Developments
  13. 8.3 Shapuaisi Pharma
  14. 8.3.1 Shapuaisi Pharma Company Information
  15. 8.3.2 Shapuaisi Pharma Business Overview
  16. 8.3.3 Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  18. 8.3.5 Shapuaisi Pharma Recent Developments
  19. 8.4 Luoxin Pharmaceutical
  20. 8.4.1 Luoxin Pharmaceutical Company Information
  21. 8.4.2 Luoxin Pharmaceutical Business Overview
  22. 8.4.3 Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  24. 8.4.5 Luoxin Pharmaceutical Recent Developments
  25. 8.5 Zydus Pharms
  26. 8.5.1 Zydus Pharms Company Information
  27. 8.5.2 Zydus Pharms Business Overview
  28. 8.5.3 Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  30. 8.5.5 Zydus Pharms Recent Developments
  31. 8.6 Teva
  32. 8.6.1 Teva Company Information
  33. 8.6.2 Teva Business Overview
  34. 8.6.3 Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  36. 8.6.5 Teva Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Avet Pharmaceuticals
  44. 8.8.1 Avet Pharmaceuticals Company Information
  45. 8.8.2 Avet Pharmaceuticals Business Overview
  46. 8.8.3 Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  48. 8.8.5 Avet Pharmaceuticals Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 Alnylam Pharmaceuticals
  56. 8.10.1 Alnylam Pharmaceuticals Company Information
  57. 8.10.2 Alnylam Pharmaceuticals Business Overview
  58. 8.10.3 Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  60. 8.10.5 Alnylam Pharmaceuticals Recent Developments
  61. 8.11 Akcea Therapeutics
  62. 8.11.1 Akcea Therapeutics Company Information
  63. 8.11.2 Akcea Therapeutics Business Overview
  64. 8.11.3 Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  66. 8.11.5 Akcea Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Value Chain Analysis
  2. 9.1.1 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Production Mode & Process
  6. 9.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Distributors
  9. 9.2.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst